Clinical trial
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04671251 is registered in ClinicalTrials.gov with Avalo Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Avalo Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 15, 2020
- Completion date
- March 30, 2022
- Enrollment
- 13 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.